Participants were randomly assigned to groups either receiving a once-per-week subcutaneous injection of tirzepatide(5 mg, 10 mg, or 15 mg) or insulin glargine (100 U/mL)
Individual data were not available for review, but the authors noted that there were very few arrythmias at baseline in their study subjects, and no significant change in dialysis-associated arrhythmias was observed
What research does show: Greater average weight reduction at higher doses Greater HbA1c reduction at higher doses Increased side effects with dose escalation What research does not yet establish: Whether ultra-low doses maintain meaningful long-term weight reduction Whether microdosing produces comparable metabolic outcomes Whether indefinite low-dose therapy is effective for maintenance Much of the online discussion is anecdotal rather than trial-based
After 8 weeks, the mechanical pain scores of rats in both the SCI and GlyNAC+SCI groups showed a significant decrease, with no significant difference being detected between the two groups ( P = 0.2857)
For brain fog and cognitive symptoms Brain fog on GLP-1 medications is often linked to a combination of dehydration, low sodium, and low magnesium
Tau-based biomarkers are expanding our understanding of the AD process and are beginning to play a greater role in clinical research settings
